Skip to main content
News Feature: Avacopan for ANCA Vasculitis Goes in Front of the FDA

An FDA advisory panel will consider whether to reco

Dr. John Cush RheumNow

5 years 4 months ago
News Feature: Avacopan for ANCA Vasculitis Goes in Front of the FDA An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for ANCA-associated vasculitis. https://t.co/66NSjbkE8Q https://t.co/9cR2lBASjz
#LupusAwarenessMonth
Dr. Kathryn Dao - Risk of Hydroxychloroquine Retinal Toxicity
From ACR 2020
https://t.co/7BCVvMOm

Dr. John Cush RheumNow

5 years 4 months ago
#LupusAwarenessMonth Dr. Kathryn Dao - Risk of Hydroxychloroquine Retinal Toxicity From ACR 2020 https://t.co/7BCVvMOm0T https://t.co/PhHubO7rxG
#LupusAwarenessMonth

Dr. Michelle Petri - Best Practices in Testing for Antiphospholipid Syndrome (LAC wins)
From AC

Dr. John Cush RheumNow

5 years 4 months ago
#LupusAwarenessMonth Dr. Michelle Petri - Best Practices in Testing for Antiphospholipid Syndrome (LAC wins) From ACR 2020 https://t.co/IyeRDzw4BC https://t.co/nSkauHf29T
New podcast alert!

Falling or Falling in Love (5.7.2021)
Dr Jack Cush reviews the best journal articles of the week

Dr. John Cush RheumNow

5 years 4 months ago
New podcast alert! Falling or Falling in Love (5.7.2021) Dr Jack Cush reviews the best journal articles of the week from RheumNow https://t.co/HyAPN2rM3L https://t.co/C5XtqthO8I
May is also arthritis awareness month!

Why we love Rheumatology Fellows
https://t.co/rNVjZZr9l4

#ArthritisAwarenessM

Dr. John Cush RheumNow

5 years 4 months ago
May is also arthritis awareness month! Why we love Rheumatology Fellows https://t.co/rNVjZZr9l4 #ArthritisAwarenessMonth
News Feature: Drug Monitoring Ineffective with Infliximab Treatment

A randomized trial compared TDM to no TDM in patie

Dr. John Cush RheumNow

5 years 5 months ago
News Feature: Drug Monitoring Ineffective with Infliximab Treatment A randomized trial compared TDM to no TDM in patients receiving infliximab for chronic IMIDs and found that TDM did not increase the odds of achieving remission. https://t.co/AVcX4EXY0l https://t.co/RlDij6ln61
An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, with agency staff raising questions over the "clinical meaningfulness" of key study data.
Falls are not uncommon in #RA patients; significant risk factors for falls include being elderly, un-married, higher pai

Dr. John Cush RheumNow

5 years 5 months ago
Falls are not uncommon in #RA patients; significant risk factors for falls include being elderly, un-married, higher pain scores, reported dizziness taking psychotropic medications and having lower HRQoL scores https://t.co/a8qA7n68q5
Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.
Today begins National Nurses week!

God Bless Rheumatology Nurses
https://t.co/JC9ExqnXEb

#ArthritisAwarenessMonth http

Dr. John Cush RheumNow

5 years 5 months ago
Today begins National Nurses week! God Bless Rheumatology Nurses https://t.co/JC9ExqnXEb #ArthritisAwarenessMonth https://t.co/bhuocIlHWT
×